ES2391107T3 - Compuestos que tienen actividad en el receptor M1 y sus usos en medicina - Google Patents

Compuestos que tienen actividad en el receptor M1 y sus usos en medicina Download PDF

Info

Publication number
ES2391107T3
ES2391107T3 ES06794587T ES06794587T ES2391107T3 ES 2391107 T3 ES2391107 T3 ES 2391107T3 ES 06794587 T ES06794587 T ES 06794587T ES 06794587 T ES06794587 T ES 06794587T ES 2391107 T3 ES2391107 T3 ES 2391107T3
Authority
ES
Spain
Prior art keywords
dihydro
benzimidazol
piperidinyl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06794587T
Other languages
English (en)
Spanish (es)
Inventor
Brian Budzik
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Jian Jin
Dongchuan Shi
Paul William Smith
Graham Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519949.2A external-priority patent/GB0519949D0/en
Priority claimed from GB0602856A external-priority patent/GB0602856D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2391107T3 publication Critical patent/ES2391107T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES06794587T 2005-09-30 2006-09-27 Compuestos que tienen actividad en el receptor M1 y sus usos en medicina Active ES2391107T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0519949.2A GB0519949D0 (en) 2005-09-30 2005-09-30 Compounds
GB0519949 2005-09-30
GB0602856 2006-02-13
GB0602856A GB0602856D0 (en) 2006-02-13 2006-02-13 Compounds
PCT/GB2006/003595 WO2007036718A2 (en) 2005-09-30 2006-09-27 Compounds which have activity at m1 receptor and their uses in medicine

Publications (1)

Publication Number Publication Date
ES2391107T3 true ES2391107T3 (es) 2012-11-21

Family

ID=37635729

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06794587T Active ES2391107T3 (es) 2005-09-30 2006-09-27 Compuestos que tienen actividad en el receptor M1 y sus usos en medicina

Country Status (8)

Country Link
US (1) US8288412B2 (cg-RX-API-DMAC7.html)
EP (1) EP1960389B1 (cg-RX-API-DMAC7.html)
JP (1) JP5209481B2 (cg-RX-API-DMAC7.html)
AR (1) AR055667A1 (cg-RX-API-DMAC7.html)
ES (1) ES2391107T3 (cg-RX-API-DMAC7.html)
PE (1) PE20070586A1 (cg-RX-API-DMAC7.html)
TW (1) TW200804355A (cg-RX-API-DMAC7.html)
WO (1) WO2007036718A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007036711A1 (en) 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
EA016286B1 (ru) * 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
EP1960389B1 (en) 2005-09-30 2012-08-15 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
GB0605784D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
US20090221567A1 (en) * 2008-02-28 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
US20090221642A1 (en) * 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
GB0817982D0 (en) 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
US20100278835A1 (en) 2009-03-10 2010-11-04 Astrazeneca Uk Limited Novel compounds 660
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN106316864A (zh) * 2016-08-22 2017-01-11 苏州天马精细化学品股份有限公司 4‑甲基‑3‑三氟甲基苯胺的制备方法
CN111848406B (zh) * 2019-04-26 2022-03-29 沈阳中化农药化工研发有限公司 一种2-氯-4-氟-5-硝基苯甲醛的制备方法
CN113637001A (zh) * 2021-08-09 2021-11-12 安康市农业科学研究院 一种氟哌利多中间体的合成方法
US20250064833A1 (en) 2021-12-13 2025-02-27 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) * 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3989707A (en) * 1974-06-21 1976-11-02 Janssen Pharmaceutica N.V. Benzimidazolinone derivatives
US4292321A (en) * 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
US4411904A (en) * 1981-05-29 1983-10-25 Warner-Lambert Company Diphenylpropanamines, compositions thereof and use thereof
DE3124366A1 (de) * 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
DE4040300A1 (de) 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP3916093B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 光学活性イミダゾリジノン誘導体とその製造方法
AU701127B2 (en) * 1994-10-27 1999-01-21 Merck & Co., Inc. Muscarine antagonists
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
AU7478396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6465484B1 (en) * 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
WO1999032481A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
ES2223588T3 (es) 1999-10-13 2005-03-01 Banyu Pharmaceutical Co., Ltd. Derivados de imidazolidinona sustituidos.
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
AU2001234705A1 (en) * 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indalone and benzimidazolone inhibitors of factor xa
ATE403431T1 (de) * 2001-04-18 2008-08-15 Euro Celtique Sa Benzimidazolon-verbindungen
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
RU2288919C2 (ru) * 2001-10-02 2006-12-10 Акадиа Фармасьютикалз, Инк. Производные бензимидазолидинона в качестве агентов мускариновых рецепторов
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037890A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
US7279490B2 (en) 2002-06-17 2007-10-09 Merck & Co, Inc. Ophthalmic compositions for treating ocular hypertension
CN1744899A (zh) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
CA2532071A1 (en) * 2003-07-23 2005-02-03 Wyeth Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands
PL1664036T3 (pl) 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
CA2586179C (en) * 2004-11-02 2011-02-08 Pfizer Inc. Sulfonyl benzimidazole derivatives
US7300947B2 (en) * 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
EA016286B1 (ru) * 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
WO2007036711A1 (en) 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
EP1960389B1 (en) 2005-09-30 2012-08-15 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
US8239995B2 (en) 2006-09-08 2012-08-14 The Gillette Company Toothbrush with multiple bristles states
GB0706164D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706190D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706188D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706189D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
JP2009510041A (ja) 2009-03-12
US20080293770A1 (en) 2008-11-27
AR055667A1 (es) 2007-08-29
TW200804355A (en) 2008-01-16
JP5209481B2 (ja) 2013-06-12
EP1960389B1 (en) 2012-08-15
WO2007036718A2 (en) 2007-04-05
US8288412B2 (en) 2012-10-16
EP1960389A2 (en) 2008-08-27
PE20070586A1 (es) 2007-06-16
WO2007036718A3 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
US8481566B2 (en) Compounds which have activity at M1 receptor and their uses in medicine
BRPI0708999A2 (pt) benzimidazóis que têm atividade em receptor m1 e seus usos em medicina
EP1960389B1 (en) Compounds which have activity at m1 receptor and their uses in medicine
ES2395532T3 (es) BENCIMIDAZOLES que tienen actividad en el receptor M1 y sus usos en medicina
JP5209479B2 (ja) M1受容体にて活性を有するベンゾイミダゾロン類
WO2008119717A1 (en) Compounds which have activity at m1 receptor and their uses in medicine
WO2008119711A1 (en) Substituted benzimidazolone compounds which have activity at m1 receptor and their uses in medicine
WO2008119714A1 (en) Compounds which have activity at m1 receptor and their uses in medicine
EP2344483B1 (en) Compounds which have activity at m1 receptor and their uses in medicine
ES2357970T3 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina.
US8344000B2 (en) Compounds which have activity at M1 receptor and their uses in medicine